Radicava (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Looking for Participants with ALS

What is the goal of this study:

To find biomarkers in blood and urine to show why Radicava (Edaravone) is slowing ALS symptom progression. Radicava was approved by the FDA as a treatment for ALS in May of 2017 and has been shown to slow the loss of physical function in ALS. In this research study, we want to learn what changes happen in patients with ALS that can be seen in blood and urine when they take Radicava. Participants must obtain insurance approval for Radicava to participate in this biomarker study.

Eligibility Criteria

- People with sporadic or familial ALS, 18 years or older
- Decision made to prescribe Edaravone prior to screening, and likely able to complete 6 cycles of treatment
- Either never received Radicava or have been off Radicava 1 month prior to screening

Exclusionary Criteria

- Contraindication to Radicava
- Participating in an interventional clinical trial

What happens if I want to participate?

- There will be 8 in-person visits over 24 weeks at the Healey Center for ALS at MGH
- Visits last 1-3 hours
- During each visit, we will collect blood and urine and there will be a series of questionnaires and assessments (breathing and muscle testing)

Remuneration

- Parking validation and reimbursement for travel to MGH on a tiered amount based on your travel distance

Please contact us if you are interested in hearing more details and/or if you would like to know if you are eligible to participate in this study.

Principal Investigator: Suma Babu, MD, MPH
Cassandra Lieberman
617-643-7428
Clieberman1@mgh.harvard.edu